Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of LVTX is 1.5 and suggests 13% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Buy
Sell